• en
  • de

Convergys® TT

Assay for the determination of the Thrombin Time (TT) in plasma.

Convergys® TT is used for the in vitro determination of the Thrombin Time (TT). It can be used for the detection of fibrinogen abnormalities and the presence of thrombin inhibitors like heparin in citrated plasma. Depending on the intended use, Convergys® TT can be solubilized in different volumes, 5 ml for the detection of fibrinogen abnormalities and 2 ml for the detection of thrombin inhibitors.

  • The TT assay is used for the assessment of fibrin formation. The added thrombin cleaves the fibrinogen present in the plasma sample to form fibrin, which subsequently polymerizes and forms a fibrin clot.
  • The time it takes for this clot to form is being measured and reported as the Thrombin Time (TT). An increased TT can indicate coagulation disorders like low plasma fibrinogen concentration, dysfibrinogenemia (abnormal fibrinogen function), presence of fibrinogen degradation products or disseminated intravascular coagulopathy (DIC).
  • In patients with an increased APTT the TT assay may be used for evaluation. Convergys® TT is a bovine thrombin, purified and freeze-dried, intended for the determination of the Thrombin Time.
  • Specifications:
  • Reproducibility: CV≤2.1 % in control runs (between and within runs)
  • Sensitivity: Heparin 0.03–0.25 IU/ml (reconstituted in 2 ml)
  • Interferences: Thrombin Time can be increased by the influence of several common drugs, among others heparin and hirudin as well as other drugs which inhibit Factor II (e.g. dabigatran). Haemolysis and bilirubin concentration also influence the TT.
  • Stability and storage conditions:
  • Shelf life: 24 months from the date of production at 2–8 °C
  • Reconstituted: 8 days at 2–8 °C, 3 days at 15–25 °C
http://convergent-technologies.de/product/convergys-tt/